46.25
price up icon1.29%   0.61
 
loading
Sanofi Adr stock is traded at $46.25, with a volume of 762.22K. It is up +1.29% in the last 24 hours and down -5.75% over the past month. Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from cardiometabolic will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs, with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
See More
Previous Close:
$45.64
Open:
$45.98
24h Volume:
762.22K
Relative Volume:
0.35
Market Cap:
$113.48B
Revenue:
$48.62B
Net Income/Loss:
$6.80B
P/E Ratio:
16.50
EPS:
2.8038
Net Cash Flow:
$7.62B
1W Performance:
-8.22%
1M Performance:
-5.75%
6M Performance:
-14.92%
1Y Performance:
-10.51%
1-Day Range:
Value
$45.97
$46.67
1-Week Range:
Value
$44.73
$49.96
52-Week Range:
Value
$44.73
$60.12

Sanofi Adr Stock (SNY) Company Profile

Name
Name
Sanofi Adr
Name
Phone
-
Name
Address
-
Name
Employee
82,878
Name
Twitter
@sanofi
Name
Next Earnings Date
2024-10-25
Name
Latest SEC Filings
Name
SNY's Discussions on Twitter

Compare SNY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
SNY
Sanofi Adr
46.22 120.12B 48.62B 6.80B 7.62B 2.8038
Drug Manufacturers - General icon
LLY
Lilly Eli Co
758.81 682.35B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
165.99 402.82B 90.63B 22.66B 16.40B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
193.84 334.40B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
114.08 225.78B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
MRK
Merck Co Inc
78.44 205.28B 63.62B 16.41B 17.04B 6.49

Sanofi Adr Stock (SNY) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-15-25 Initiated Exane BNP Paribas Outperform
Mar-21-25 Initiated Goldman Neutral
Jan-30-25 Upgrade Deutsche Bank Sell → Hold
Jul-26-24 Reiterated Argus Buy
Jan-23-24 Initiated Morgan Stanley Equal-Weight
Jan-16-24 Resumed UBS Buy
Dec-05-23 Downgrade JP Morgan Overweight → Neutral
Oct-30-23 Downgrade Stifel Buy → Hold
Sep-06-23 Upgrade Berenberg Hold → Buy
Jul-14-23 Initiated HSBC Securities Buy
Apr-28-23 Downgrade Deutsche Bank Hold → Sell
Mar-27-23 Upgrade Barclays Equal Weight → Overweight
Dec-13-22 Resumed Morgan Stanley Overweight
Aug-12-22 Upgrade Deutsche Bank Sell → Hold
Aug-09-22 Downgrade UBS Buy → Neutral
May-23-22 Initiated SVB Leerink Outperform
Sep-27-21 Upgrade SVB Leerink Mkt Perform → Outperform
Jan-15-21 Initiated Deutsche Bank Sell
Sep-29-20 Initiated Berenberg Hold
Mar-17-20 Upgrade Barclays Underweight → Equal Weight
Mar-11-20 Upgrade Goldman Neutral → Buy
Feb-11-20 Initiated SVB Leerink Mkt Perform
Jan-06-20 Upgrade JP Morgan Neutral → Overweight
Sep-23-19 Upgrade Guggenheim Neutral → Buy
Sep-20-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-03-19 Initiated Bernstein Outperform
Aug-14-19 Upgrade UBS Neutral → Buy
Dec-11-18 Upgrade Jefferies Hold → Buy
Nov-01-18 Upgrade Barclays Underweight → Equal Weight
Oct-09-18 Initiated Guggenheim Neutral
Sep-10-18 Upgrade BofA/Merrill Neutral → Buy
Aug-10-18 Upgrade Citigroup Neutral → Buy
Mar-23-18 Upgrade Liberum Hold → Buy
Jan-23-18 Downgrade Barclays Equal Weight → Underweight
Dec-06-17 Downgrade BofA/Merrill Buy → Neutral
Dec-01-17 Downgrade Morgan Stanley Overweight → Underweight
Nov-15-17 Upgrade Barclays Underweight → Equal Weight
Aug-30-17 Upgrade HSBC Securities Reduce → Hold
View All

Sanofi Adr Stock (SNY) Latest News

pulisher
Jul 31, 2025

Sanofi ADR (SNY) Stock: A Year of Stock Market Ups and Downs - investchronicle.com

Jul 31, 2025
pulisher
Jul 31, 2025

Sanofi ADR earnings beat by $0.63, revenue fell short of estimates - Investing.com Nigeria

Jul 31, 2025
pulisher
Jul 29, 2025

Hematologist Dissatisfaction with Current Warm Autoimmune Hemolytic Anemia (w-AIHA) Treatment Spurs Interest in Late-Stage Pipeline, According to Spherix Global Insights - GlobeNewswire Inc.

Jul 29, 2025
pulisher
Jul 27, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SanofiSNY - cnhinews.com

Jul 27, 2025
pulisher
Jul 24, 2025

Sanofi: Reassessing Our Moat Rating for This Leader in Immunology, Vaccines, and Rare Diseases - Morningstar

Jul 24, 2025
pulisher
Jul 24, 2025

Dupixent Leads the Charge for Sanofi's Strong Portfolio in Immunology, Vaccines, and Rare Diseases - Morningstar

Jul 24, 2025
pulisher
Jul 22, 2025

BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study - Ariva

Jul 22, 2025
pulisher
Jul 21, 2025

AstraZeneca pledges $50 bln investment in US as pharma tariffs loom By Investing.com - Investing.com

Jul 21, 2025
pulisher
Jul 01, 2025

Adagene stock gains as Sanofi expands agreement (ADAG:NASDAQ) - Seeking Alpha

Jul 01, 2025
pulisher
Jun 13, 2025

SNY’s 2023 Market Dance: Up 3.92% – Time to Invest? - investchronicle.com

Jun 13, 2025
pulisher
Jun 09, 2025

Sanofi: Information concerning the total number of voting rights and shares - GlobeNewswire Inc.

Jun 09, 2025
pulisher
Jun 02, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Jun 02, 2025
pulisher
Jun 02, 2025

France’s Sanofi to buy U.S. biopharma group Blueprint for up to $9.5-billion - The Globe and Mail

Jun 02, 2025
pulisher
Jun 02, 2025

Sanofi doubles down on immunology with $9.1bn Blueprint deal - Proactive financial news

Jun 02, 2025
pulisher
May 31, 2025

European ADR Index Slips As Pharma Stocks Buck The Trend - Finimize

May 31, 2025
pulisher
May 30, 2025

Regeneron and Sanofi: Disappointing Top-Line Results for Itepekimab From Two Phase 3 Trials - Morningstar

May 30, 2025
pulisher
May 30, 2025

Regeneron Pharmaceuticals Crashes 19% On A Surprise Sanofi-Tied Failure - Investor's Business Daily

May 30, 2025
pulisher
May 30, 2025

Market movers: Canopy Growth, Zscaler, Regeneron... - Proactive financial news

May 30, 2025
pulisher
May 30, 2025

Regeneron shares plunge after mixed COPD drug trial results - Proactive financial news

May 30, 2025
pulisher
May 29, 2025

Penicillin Market Research Report 2025 - GlobeNewswire Inc.

May 29, 2025
pulisher
May 29, 2025

Sanofi: New Anthem from Girl Band Raises Awareness of Type 1 Diabetes After Research Highlights Silent Struggle - Ariva

May 29, 2025
pulisher
May 26, 2025

Prurigo Nodularis Market - GlobeNewswire Inc.

May 26, 2025
pulisher
May 23, 2025

8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.

May 23, 2025
pulisher
May 22, 2025

Dollar Stock Biotech Triples On $470 Million Sanofi Takeover - Investor's Business Daily

May 22, 2025
pulisher
May 08, 2025

Metric Deep Dive: Understanding Sanofi ADR (SNY) Through its Ratios - DWinneX

May 08, 2025
pulisher
May 02, 2025

iRhythm Technologies Inc (IRTC) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com

May 02, 2025
pulisher
May 02, 2025

WLK’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com

May 02, 2025
pulisher
May 02, 2025

BIDU’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

May 02, 2025

Sanofi Adr Stock (SNY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general PFE
$23.20
price down icon 0.49%
$112.54
price up icon 0.10%
$294.42
price down icon 0.43%
drug_manufacturers_general NVO
$47.75
price up icon 1.38%
drug_manufacturers_general MRK
$78.48
price up icon 0.17%
Cap:     |  Volume (24h):